How to follow-up a patient who received tocilizumab in severe COVID-19: a case report
Abstract Background COVID-19 is characterized by fast deterioration in the mechanism of cytokine storm. Therefore, treatment with immunomodulating agents should be initiated as soon as hyperinflammation is established. Evidence for the use of tocilizumab (TCZ) in COVID-19 is emerging, but the drug i...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2020-08-01
|
| Rangatū: | European Journal of Medical Research |
| Ngā marau: | |
| Urunga tuihono: | http://link.springer.com/article/10.1186/s40001-020-00438-x |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|